Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use

INTRODUCTION: Response to current therapy of hepatitis C virus (HCV) is suboptimal. Direct-acting antiviral therapies (DAA) are expected to improve treatment outcomes. Additional treatments for HCV will invariably make therapeutic choices and patient management more complex. We hypothesize that curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaglio, Paul J., Moss, Noah, McGaw, Camille, Reinus, John
Formato: Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082020/
https://www.ncbi.nlm.nih.gov/pubmed/21336604
http://dx.doi.org/10.1007/s10620-011-1604-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3082020/
https://www.ncbi.nlm.nih.gov/pubmed/21336604
http://dx.doi.org/10.1007/s10620-011-1604-3

Ejemplares similares